Literature DB >> 16461762

Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.

Anas Younes, Barbara Pro, Luis Fayad.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16461762     DOI： 10.1182/blood-2005-09-3731

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  14 in total

Review 1.  Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway.

Authors:  Carlos Camps; Vega Iranzo; Roy M Bremnes; Rafael Sirera
Journal:  Support Care Cancer       Date:  2006-07-04       Impact factor: 3.603

2.  Novel therapies for Hodgkin Lymphoma.

Authors:  John W Sweetenham
Journal:  Ther Adv Hematol       Date:  2010-02

Review 3.  Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.

Authors:  Radhakrishnan Ramchandren
Journal:  Oncologist       Date:  2012-03-02

4.  The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.

Authors:  Juan J Gu; Francisco J Hernandez-Ilizaliturri; Gregory P Kaufman; Natalie M Czuczman; Cory Mavis; Joseph J Skitzki; Myron S Czuczman
Journal:  Br J Haematol       Date:  2013-07-04       Impact factor: 6.998

Review 5.  Beyond chemotherapy: new agents for targeted treatment of lymphoma.

Authors:  Anas Younes
Journal:  Nat Rev Clin Oncol       Date:  2010-12-14       Impact factor: 66.675

6.  Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial.

Authors:  Meghan Karuturi; Anas Younes; Luis Fayad; Larry Kwak; Barbara Pro; Jatin Shah; Yasuhiro Oki; Rinata Simien; Mary Joy Liboon; Toni Hutto; Lei Feng; Sandra Horowitz; Yago Nieto; Paolo Anderlini; Amin Alousi; Uday Popat; L Jeffrey Medeiros; Roberto Miranda; Michelle Fanale
Journal:  Leuk Lymphoma       Date:  2015-03-25

Review 7.  Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.

Authors:  Adam Jona; Anas Younes
Journal:  Blood Rev       Date:  2010-09-15       Impact factor: 8.250

8.  EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis.

Authors:  Ting-Yun Liu; Shang-Ju Wu; Mi-Hsin Huang; Fei-Yun Lo; Mong-Hsun Tsai; Ching-Hwa Tsai; Su-Ming Hsu; Chung-Wu Lin
Journal:  Mol Cancer       Date:  2010-02-09       Impact factor: 27.401

Review 9.  Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options.

Authors:  Kevin A David; Lauren Mauro; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2007-10

Review 10.  Clinical development of novel proteasome inhibitors for cancer treatment.

Authors:  Huanjie Yang; Jeffrey A Zonder; Q Ping Dou
Journal:  Expert Opin Investig Drugs       Date:  2009-07       Impact factor: 6.206
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.